303 related articles for article (PubMed ID: 32074448)
1. Effect of Manufacturing Variables and Raw Materials on the Composition-Equivalent PLGA Microspheres for 1-Month Controlled Release of Leuprolide.
Zhou J; Walker J; Ackermann R; Olsen K; Hong JKY; Wang Y; Schwendeman SP
Mol Pharm; 2020 May; 17(5):1502-1515. PubMed ID: 32074448
[TBL] [Abstract][Full Text] [Related]
2. Reverse Engineering the 1-Month Lupron Depot®.
Zhou J; Hirota K; Ackermann R; Walker J; Wang Y; Choi S; Schwendeman A; Schwendeman SP
AAPS J; 2018 Oct; 20(6):105. PubMed ID: 30280294
[TBL] [Abstract][Full Text] [Related]
3. Development of Level A in vitro-in vivo correlations for peptide loaded PLGA microspheres.
Andhariya JV; Jog R; Shen J; Choi S; Wang Y; Zou Y; Burgess DJ
J Control Release; 2019 Aug; 308():1-13. PubMed ID: 31301338
[TBL] [Abstract][Full Text] [Related]
4. In vitro-in vivo correlation of parenteral PLGA microspheres: Effect of variable burst release.
Andhariya JV; Jog R; Shen J; Choi S; Wang Y; Zou Y; Burgess DJ
J Control Release; 2019 Nov; 314():25-37. PubMed ID: 31654687
[TBL] [Abstract][Full Text] [Related]
5. Development and characterization of composition-equivalent formulations to the Sandostatin LAR® by the solvent evaporation method.
Beig A; Feng L; Walker J; Ackermann R; Hong JKY; Li T; Wang Y; Schwendeman SP
Drug Deliv Transl Res; 2022 Mar; 12(3):695-707. PubMed ID: 34215997
[TBL] [Abstract][Full Text] [Related]
6. Mechanistic evaluation of the initial burst release of leuprolide from spray-dried PLGA microspheres.
Schutzman R; Shi NQ; Olsen KF; Ackermann R; Tang J; Liu YY; Hong JKY; Wang Y; Qin B; Schwendeman A; Schwendeman SP
J Control Release; 2023 Sep; 361():297-313. PubMed ID: 37343723
[TBL] [Abstract][Full Text] [Related]
7. Microencapsulation of luteinizing hormone-releasing hormone agonist in poly (lactic-co-glycolic acid) microspheres by spray-drying.
Shi NQ; Zhou J; Walker J; Li L; Hong JKY; Olsen KF; Tang J; Ackermann R; Wang Y; Qin B; Schwendeman A; Schwendeman SP
J Control Release; 2020 May; 321():756-772. PubMed ID: 31935481
[TBL] [Abstract][Full Text] [Related]
8. Physical-Chemical Characterization of Octreotide Encapsulated in Commercial Glucose-Star PLGA Microspheres.
Beig A; Feng L; Walker J; Ackermann R; Hong JKY; Li T; Wang Y; Qin B; Schwendeman SP
Mol Pharm; 2020 Nov; 17(11):4141-4151. PubMed ID: 32876463
[TBL] [Abstract][Full Text] [Related]
9. Influence of PLGA molecular weight distribution on leuprolide release from microspheres.
Ochi M; Wan B; Bao Q; Burgess DJ
Int J Pharm; 2021 Apr; 599():120450. PubMed ID: 33675924
[TBL] [Abstract][Full Text] [Related]
10. Polymer source affects in vitro-in vivo correlation of leuprolide acetate PLGA microspheres.
Wan B; Bao Q; Wang R; Burgess DJ
Int J Pharm; 2022 Sep; 625():122032. PubMed ID: 35878870
[TBL] [Abstract][Full Text] [Related]
11. Minimizing the initial burst of octreotide acetate from glucose star PLGA microspheres prepared by the solvent evaporation method.
Beig A; Ackermann R; Wang Y; Schutzman R; Schwendeman SP
Int J Pharm; 2022 Aug; 624():121842. PubMed ID: 35609832
[TBL] [Abstract][Full Text] [Related]
12. In vitro performance of composition-equivalent PLGA microspheres encapsulating exenatide acetate by solvent evaporation.
Chandrashekar A; Beig A; Wang Y; Schwendeman SP
Int J Pharm; 2023 Aug; 643():123213. PubMed ID: 37423376
[TBL] [Abstract][Full Text] [Related]
13. Effect of polymer source on in vitro drug release from PLGA microspheres.
Wan B; Andhariya JV; Bao Q; Wang Y; Zou Y; Burgess DJ
Int J Pharm; 2021 Sep; 607():120907. PubMed ID: 34332059
[TBL] [Abstract][Full Text] [Related]
14. Aqueous remote loading of model cationic peptides in uncapped poly(lactide-co-glycolide) microspheres for long-term controlled release.
Liang D; Frank S; Schwendeman SP
Drug Deliv Transl Res; 2024 Mar; 14(3):696-704. PubMed ID: 38038895
[TBL] [Abstract][Full Text] [Related]
15. Characterizing release mechanisms of leuprolide acetate-loaded PLGA microspheres for IVIVC development I: In vitro evaluation.
Hirota K; Doty AC; Ackermann R; Zhou J; Olsen KF; Feng MR; Wang Y; Choi S; Qu W; Schwendeman AS; Schwendeman SP
J Control Release; 2016 Dec; 244(Pt B):302-313. PubMed ID: 27565212
[TBL] [Abstract][Full Text] [Related]
16. In vivo evaluation of solid lipid microparticles and hybrid polymer-lipid microparticles for sustained delivery of leuprolide.
Wu C; Luo X; Baldursdottir SG; Yang M; Sun X; Mu H
Eur J Pharm Biopharm; 2019 Sep; 142():315-321. PubMed ID: 31299277
[TBL] [Abstract][Full Text] [Related]
17. Poly(lactic-co-glycolic acid) microsphere production based on quality by design: a review.
Hua Y; Su Y; Zhang H; Liu N; Wang Z; Gao X; Gao J; Zheng A
Drug Deliv; 2021 Dec; 28(1):1342-1355. PubMed ID: 34180769
[TBL] [Abstract][Full Text] [Related]
18. Characterization of attributes and in vitro performance of exenatide-loaded PLGA long-acting release microspheres.
Li T; Chandrashekar A; Beig A; Walker J; Hong JKY; Benet A; Kang J; Ackermann R; Wang Y; Qin B; Schwendeman AS; Schwendeman SP
Eur J Pharm Biopharm; 2021 Jan; 158():401-409. PubMed ID: 33122118
[TBL] [Abstract][Full Text] [Related]
19. The effect of PLGA molecular weight differences on risperidone release from microspheres.
Kohno M; Andhariya JV; Wan B; Bao Q; Rothstein S; Hezel M; Wang Y; Burgess DJ
Int J Pharm; 2020 May; 582():119339. PubMed ID: 32305366
[TBL] [Abstract][Full Text] [Related]
20. Goserelin Acetate Loaded Poloxamer Hydrogel in PLGA Microspheres: Core-Shell Di-Depot Intramuscular Sustained Release Delivery System.
Qi P; Bu R; Zhang H; Yin J; Chen J; Zhang A; Gou J; Yin T; Zhang Y; He H; Wang P; Tang X; Wang Y
Mol Pharm; 2019 Aug; 16(8):3502-3513. PubMed ID: 31251642
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
